Loading...
MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance
Menon, Nitin Naylor, Isabelle Buba, Emmanuel Schena, Alberto Morgan, Paul S Fox, Christopher P Thust, Stefanie
Menon, Nitin
Naylor, Isabelle
Buba, Emmanuel
Schena, Alberto
Morgan, Paul S
Fox, Christopher P
Thust, Stefanie
Abstract
INTRODUCTION: Despite treatment advances, accurate prognostication for patients with newly diagnosed primary central nervous system lymphoma (PCNSL) remains unsatisfactory. This retrospective cohort study evaluated whether T1 contrast-enhanced (T1CE) tumour volume and apparent diffusion coefficient (ADC) metrics on magnetic resonance imaging (MRI) predict survival in PCNSL patients treated uniformly with MATRix chemotherapy.
METHODS: Sixty-five patients underwent pre-treatment MRI with volumetric and diffusion analysis. T1CE tumour volume, ADCmean, ADCmin and normalised diffusion parameters were assessed. Survival outcomes were analysed using univariate Cox regression for overall survival (OS) and progression-free survival (PFS), including disease-specific endpoints.
RESULTS: None of the tested imaging variables were significantly associated with OS or PFS, including T1CE tumour volume and ADC measures. Baseline T1CE and diffusion biomarkers did not predict survival in MATRix-treated PCNSL.
DISCUSSION: These results highlight limitations of standard MRI techniques for prognostication underscoring the need for integrated multiparametric models incorporating imaging and biological data to improve outcome prediction.
Affiliations
Date
2026-06-25
Type
Article
Subject
Collections
Citation
Menon N, Naylor I, Buba E, Schena A, Morgan PS, Fox CP, Thust S. MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance. Front Oncol. 2026 Jun 25;16:1769381. doi: 10.3389/fonc.2026.1769381